Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome

Objective: To evaluate the effect of the GnRH antagonist on gonadotropin ovulation induction in women with PCOS. Materials and methods: A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study. Women in the control group (n = 87)...

Full description

Bibliographic Details
Main Authors: Runa Ozelci, Serdar Dilbaz, Berna Dilbaz, Derya Akdag Cırık, Saynur Yılmaz, Ozlem Moraloglu Tekin
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Taiwanese Journal of Obstetrics & Gynecology
Online Access:http://www.sciencedirect.com/science/article/pii/S1028455919300129
id doaj-d2052e0bb45642b190e906001be90e98
record_format Article
spelling doaj-d2052e0bb45642b190e906001be90e982020-11-25T00:14:09ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592019-03-01582234238Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndromeRuna Ozelci0Serdar Dilbaz1Berna Dilbaz2Derya Akdag Cırık3Saynur Yılmaz4Ozlem Moraloglu Tekin5Corresponding author. Yeni Etlik Caddesi, Etlik, Ankara, 06010, Turkey.; Department of Reproductive Endocrinology and Infertility, Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology and Infertility, Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology and Infertility, Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology and Infertility, Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology and Infertility, Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology and Infertility, Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, TurkeyObjective: To evaluate the effect of the GnRH antagonist on gonadotropin ovulation induction in women with PCOS. Materials and methods: A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study. Women in the control group (n = 87) underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (r-FSH) only, while women in the study group (n = 88) were administered r-FSH plus cetrorelix. Results: As expected, the mean value of luteinizing hormone and progesterone, on the day of human chorionic gonadotropin administration were statistically significantly lower in patients receiving GnRH antagonist than the control group (p = 0.002). Premature luteinization occurred in only one of the patients in the GnRH antagonist group (1.1%) and in 15 of the 88 cycles in the control group (17.2%), showing a significant difference between the two groups (P = 0.001). The clinical pregnancy rate per cycle was higher in GnRH-antagonist group compared to the control group but the difference did not reach to a statistical significance (25% vs 14.9%, P = 0.096). Conclusions: Adding GnRH-antagonist in COS/IUI cycles in women with PCOS resulted in a lower incidence of premature luteinization but did not improve pregnancy rates. However, owing to some benefits, antagonist therapy could be considered as a reasonable alternative to IVF in order to reduce PCOS patients'emotional distress. Keywords: Controlled ovarian hyperstimulation, GnRH antagonist, In vitro fertilization, PCOS, Premature luteinizationhttp://www.sciencedirect.com/science/article/pii/S1028455919300129
collection DOAJ
language English
format Article
sources DOAJ
author Runa Ozelci
Serdar Dilbaz
Berna Dilbaz
Derya Akdag Cırık
Saynur Yılmaz
Ozlem Moraloglu Tekin
spellingShingle Runa Ozelci
Serdar Dilbaz
Berna Dilbaz
Derya Akdag Cırık
Saynur Yılmaz
Ozlem Moraloglu Tekin
Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
Taiwanese Journal of Obstetrics & Gynecology
author_facet Runa Ozelci
Serdar Dilbaz
Berna Dilbaz
Derya Akdag Cırık
Saynur Yılmaz
Ozlem Moraloglu Tekin
author_sort Runa Ozelci
title Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
title_short Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
title_full Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
title_fullStr Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
title_full_unstemmed Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
title_sort gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome
publisher Elsevier
series Taiwanese Journal of Obstetrics & Gynecology
issn 1028-4559
publishDate 2019-03-01
description Objective: To evaluate the effect of the GnRH antagonist on gonadotropin ovulation induction in women with PCOS. Materials and methods: A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study. Women in the control group (n = 87) underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (r-FSH) only, while women in the study group (n = 88) were administered r-FSH plus cetrorelix. Results: As expected, the mean value of luteinizing hormone and progesterone, on the day of human chorionic gonadotropin administration were statistically significantly lower in patients receiving GnRH antagonist than the control group (p = 0.002). Premature luteinization occurred in only one of the patients in the GnRH antagonist group (1.1%) and in 15 of the 88 cycles in the control group (17.2%), showing a significant difference between the two groups (P = 0.001). The clinical pregnancy rate per cycle was higher in GnRH-antagonist group compared to the control group but the difference did not reach to a statistical significance (25% vs 14.9%, P = 0.096). Conclusions: Adding GnRH-antagonist in COS/IUI cycles in women with PCOS resulted in a lower incidence of premature luteinization but did not improve pregnancy rates. However, owing to some benefits, antagonist therapy could be considered as a reasonable alternative to IVF in order to reduce PCOS patients'emotional distress. Keywords: Controlled ovarian hyperstimulation, GnRH antagonist, In vitro fertilization, PCOS, Premature luteinization
url http://www.sciencedirect.com/science/article/pii/S1028455919300129
work_keys_str_mv AT runaozelci gonadotropinreleasinghormoneantagonistuseincontrolledovarianstimulationandintrauterineinseminationcyclesinwomenwithpolycysticovarysyndrome
AT serdardilbaz gonadotropinreleasinghormoneantagonistuseincontrolledovarianstimulationandintrauterineinseminationcyclesinwomenwithpolycysticovarysyndrome
AT bernadilbaz gonadotropinreleasinghormoneantagonistuseincontrolledovarianstimulationandintrauterineinseminationcyclesinwomenwithpolycysticovarysyndrome
AT deryaakdagcırık gonadotropinreleasinghormoneantagonistuseincontrolledovarianstimulationandintrauterineinseminationcyclesinwomenwithpolycysticovarysyndrome
AT saynuryılmaz gonadotropinreleasinghormoneantagonistuseincontrolledovarianstimulationandintrauterineinseminationcyclesinwomenwithpolycysticovarysyndrome
AT ozlemmoraloglutekin gonadotropinreleasinghormoneantagonistuseincontrolledovarianstimulationandintrauterineinseminationcyclesinwomenwithpolycysticovarysyndrome
_version_ 1725391348057505792